By Sheri Kasprzak
New York, Nov. 7 - Introgen Therapeutics, Inc. wrapped a direct placement of its stock for $6,099,995 million.
The company sold 1,326,086 shares to an institutional investor at $4.60 each.
The shares will be issued under the company's shelf registration.
Mulier Capital was the placement agent.
Proceeds will be used for the clinical development of Advexin, INGN 241 and its other program. The remainder will be used for working capital and general corporate purposes.
Based in Austin, Texas, Introgen develops targeted molecular therapies to treat cancer and other diseases.
| Issuer: | Introgen Therapeutics, Inc.
|
| Issue: | Stock
|
| Amount: | $6,099,995
|
| Shares: | 1,326,086
|
| Price: | $4.60
|
| Warrants: | No
|
| Placement agent: | Mulier Capital
|
| Settlement date: | Nasdaq: INGN
|
| Stock price: | $4.93 at close Nov. 7
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
